Showing results (361-370 of 398) with videos related to

Sort By:
Pageof 40
Targeted Oncology|August 6, 2024
Pembrolizumab in Patients with Advanced Urothelial Carcinoma with ECOG Performance Status 2: A Real-World Study from the ARON-2 ProjectAlessandro Rizzo, Fernando Sabino Marques Monteiro, Yüksel Ürün, et al.
Acta Oncologica (Stockholm, Sweden)|December 14, 2011
Imatinib efficacy by tumor genotype in Korean patients with advanced gastrointestinal stromal tumors (GIST): The Korean GIST Study Group (KGSG) studyHye Jin Kang, Min-Hee Ryu, Kyoung-Mee Kim, et al.
Nature|July 1, 2026
Casdatifan shows durable response linked to HIF-2α biology in kidney cancerToni K Choueiri, Jamie Merchan, Amita Patnaik, et al.
Oncotarget|August 23, 2015
Patient-derived cell models as preclinical tools for genome-directed targeted therapyJi Yun Lee, Sun Young Kim, Charny Park, et al.
Oncotarget|September 17, 2015
Gastrointestinal malignancies harbor actionable MET exon 14 deletionsJeeyun Lee, Sai-Hong Ignatius Ou, Ji Min Lee, et al.
Investigational New Drugs|January 29, 2014
Effect of simvastatin plus cetuximab/irinotecan for KRAS mutant colorectal cancer and predictive value of the RAS signature for treatment response to cetuximabJeeyun Lee, Yong Sang Hong, Jung Yong Hong, et al.
Cancer Research and Treatment|September 2, 2015
A Retrospective Analysis for Patients with HER2-Positive Gastric Cancer Who Were Treated with Trastuzumab-Based Chemotherapy: In the Perspectives of Ethnicity and HistologyJun Ho Yi, Jung Hun Kang, In Gyu Hwang, et al.
International Journal of Cancer|November 4, 2025
Toxicity-related immunotherapy discontinuation and outcome in patients with advanced renal cell carcinoma treated with immune-based combinations (ARON-1 study)Javier Molina-Cerrillo, Giandomenico Roviello, Maria T Bourlon, et al.
Plos One|March 7, 2014
Nanostring-based multigene assay to predict recurrence for gastric cancer patients after surgeryJeeyun Lee, Insuk Sohn, In-Gu Do, et al.
Lancet (London, England)|May 18, 2020
Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trialMatthew D Galsky, José Ángel Arranz Arija, Aristotelis Bamias, et al.
Pageof 40